ArticleMolecular endocrinology (Baltimore, Md.)2012
V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.
Article in Molecular endocrinology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 48 citations in OpenAlex.
- A pharmacological and brain imaging study of human vasopressin AVP1BR receptor functional polymorphisms.BMC neuroscience · 2025Article
- The Interaction of Vasopressin with Hormones of the Hypothalamo-Pituitary-Adrenal Axis: The Significance for Therapeutic Strategies in Cardiovascular and Metabolic Diseases.International journal of molecular sciences · 2024Review
- Corticotropin releasing factor and drug seeking in substance use disorders: Preclinical evidence and translational limitations.Addiction neuroscience · 2022Article
- Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation.International journal of molecular sciences · 2021Review
- Considering Sex as a Biological Variable in Basic and Clinical Studies: An Endocrine Society Scientific Statement.Endocrine reviews · 2021Article
- Review
- Identification of avian vasotocin receptor subtype-specific antagonists involved in the stress response of the chicken, Gallus gallus.Journal of biomolecular structure & dynamics · 2019Article
- Oligomeric Receptor Complexes and Their Allosteric Receptor-Receptor Interactions in the Plasma Membrane Represent a New Biological Principle for Integration of Signals in the CNS.Frontiers in molecular neuroscience · 2019Article
- Actin cytoskeleton-dependent regulation of corticotropin-releasing factor receptor heteromers.Molecular biology of the cell · 2017Article
- Endocrinology and the brain: corticotropin-releasing hormone signaling.Endocrine connections · 2017Review
- Social Context, Stress, Neuropsychiatric Disorders, and the Vasopressin 1b Receptor.Frontiers in neuroscience · 2017Review
- Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Review
- The specific monomer/dimer equilibrium of the corticotropin-releasing factor receptor type 1 is established in the endoplasmic reticulum.The Journal of biological chemistry · 2014Article
- Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.British journal of pharmacology · 2013Article
- Family-based study of AVPR1B association and interaction with stressful life events on depression and anxiety in suicide attempts.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- CRHR1 genotypes, neural circuits and the diathesis for anxiety and depression.Molecular psychiatry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasopressin (AVP) and CRH synergistically regulate adrenocorticotropin and insulin release at the level of the pituitary and pancreas, respectively. Here, we first extended these AVP and CRH coregulation processes to the adrenal medulla. We demonstrate that costimulation of chromaffin cells by AVP and CRH simultaneously induces a catecholamine secretion exceeding the one induced by each hormone alone, thus demonstrating a net potentiation. To further elucidate the molecular mechanisms underlying this synergism, we coexpressed human V1b and CRH receptor (CRHR)1 receptor in HEK293 cells. In this heterologous system, AVP also potentiated CRH-stimulated cAMP accumulation in a dose-dependent and saturable manner. This effect was only partially mimicked by phorbol ester or inhibited by a phospholipase C inhibitor respectively. This finding suggests the existence of an new molecular mechanism, independent from second messenger cross talk. Similarly, CRH potentiated the AVP-induced inositol phosphates production. Using bioluminescence resonance energy transfer, coimmunoprecipitation, and receptor rescue experiments, we demonstrate that V1b and CRHR1 receptors assemble as heterodimers. Moreover, new pharmacological properties emerged upon receptors cotransfection. Taken together, these data strongly suggest that direct molecular interactions between V1b and CRHR1 receptors play an important role in mediating the synergistic interactions between these two receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.